The Worldwide Pneumonia Therapeutics Industry is Expected to Reach $25+ Million by 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pneumonia Therapeutics Market by Therapeutics, Distribution Channel, and Age Group: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.

The global pneumonia therapeutics market was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.

Pneumonia is an infection that affects the lower respiratory tract. Furthermore, pneumonia is characterized by symptoms such as short breathing, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that cause inflammation. It is majorly caused by microorganisms such as fungi, bacteria, virus, and parasites, and mostly affects people with weakened immune systems, and is common in children and older people.

The growth of the global pneumonia therapeutics market is majorly driven by rise in incidence of pneumonia. In addition, increase in prevalence community-acquired pneumonia is expected to propel the industry growth during the forecast period. Furthermore, increase in product launches after FDA approval is expected to help the industry gain maximum revenue. In addition, surge in clinical trials for the R&D of for development of vaccines and drug molecules is projected to help the industry grow in the next few years. However, implementation of stringent regulations for vaccines and drugs hinders the market growth.

The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines, and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is segregated into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

Market Dynamics

Drivers

• Increase in prevalence of pneumonia
• Upsurge in geriatric population with weaker immune systems
• Increase in incidence and spending for community-acquired pneumonia
• Surge in number of product launches

Restraint

• High price of pneumonia therapeutics

Opportunity

• Outbreak of novel viruses attacking respiratory system

Key Players Profiled

• Abbott Laboratories
• Bayer AG
• Eli Lilly & Company
• Glaxosmithkline Plc.
• Lupin Pharmaceuticals, Inc.
• Merck KGAA
• Novartis AG
• Pfizer, Inc.
• Sanofi S.A.
• Teva Pharmaceuticals Industries Limited

For more information about this report visit https://www.researchandmarkets.com/r/gg7xc1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900